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Abstract 
 
Introduction: Mycobacterium bovis BCG instillations are used in bladder cancer treatment. Adverse effects can 
occur. Osteoarticular complications are mainly reactive arthritis, but true infections have been described, such as 
vertebral osteomyelitis. 
 
Methods: We made a review of M. bovis BCG vertebral osteomyelitis after instillations for bladder cancer using 
PubMed search. We added 3 new French cases. 
 
Review: Twenty-seven cases of BCG vertebral osteomyelitis had been reported on PubMed. Of the 30 cases, all 
were male, averaging 73.4 ± 8.7 year-old. Median time between diagnosis and first and last instillation was 22.5 
months and 14 months respectively. Half of vertebral osteomyelitis was thoracic, and lumbar in the other half. 
Sensitivomotor deficit was present at diagnosis in 42% of cases. Other infectious locations were common, 
mainly infectious abdominal aortic aneurysms (20%). Rifampicin, ethambutol and isoniazid were the usual 
therapy. Poor outcomes were reported with 50% of one or more spine surgery. 
 
Conclusion: M. bovis BCG vertebral osteomyelitis following bladder instillation for bladder cancer is a rare 
complication. However, the late onset of back pain after instillations differentiates them from reactive arthritis. 
Concomitant septic location such as infectious abdominal aortic aneurysms must be known. 
 
 
 
Keywords: Bladder cancer, BCG-instillation, Mycobacterium bovis, vertebral osteomyelitis, Interferon-γ release 
assay 
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1. Introduction 
 
 Mycobacterium tuberculosis is the most frequent pathogen of vertebral osteomyelitis worldwide [1], and 
represent half of osteoarticular tuberculous infections [2]. In the past decades in developed countries, the 
incidence of tuberculosis in spinal infections decreased, involving 6% of vertebral osteomyelitis[3]. 
Bacillus Calmette-Guérin (BCG) is a strain obtained from Mycobacterium bovis, used for vaccination 
and immunotherapy for bladder cancer since 1976 [4]. Complications of bladder instillations occur in about 5% 
or less of patients [5], mainly with local urinary adverse effects such as pollakiuria, cystitis or haematuria. 
Systemic reactions with spinal involvement such as Reactive Arthritis (ReA) [6] can appears in weeks 
following instillations. Two principal clinical patterns were described: symmetric or asymmetric polyarthritis 
(involving small or large and upper–lower joints are more common than asymmetric mono-oligoarthritis the 
large joints of lower limbs (especially, knee and ankle). Actually, ReA after BCG bladder instillations cannot be 
fully integrated in the spondyloarthritis concept, because clinical patterns are less correlated with HLA B27 
status, if compared with ReA from enteric and urogenital infections, and the sacro-iliac or spinal involvement are 
rarer [6]. 
However, ReA after BCG bladder instillations are not the only osteoarticular events described in 
literature, and true infections such as mycobacterial vertebral osteomyelitis have also been described. Therefore, 
we performed a literature review of 27 cases previously published [7–33], and we had three original French 
cases. 
 
2. Original cases 
 
A. Case 1 
 A 65-year-old male was admitted to Pontoise hospital in January 2014 for low back pain which lasted 
for three months. His medical history included weaned smoking, hypertension, and a non-infiltrating urothelial 
carcinoma of the bladder. He was treated from December 2012 to March 2013 with six BCG instillations. Low 
back pain began rapidly, 6 months after the end of BCG instillation without any other triggering factor. He had 
lost eight kilos in three months and developed night sweats. A first X-ray showed moderate osteoarthritis of the 
spine. In December 2013, Magnetic Resonance Imaging (MRI) was performed. An inflammatory signal of L3 
and L2 vertebral bodies and L2-L3 discs was found, with slight soft tissue reaction. Metastatic bone involvement 
was first suspected.  
 The physical examination on his admission in the rheumatology unit showed limited multidirectional 
lumbar mobility of the lumbar spine, without neurological deficit. The rest of the medical examination was 
normal. C-reactive protein (CRP) was high, at 123 mg/L. A PET-scan was performed. It showed an intense 
uptake of L2 and L3 vertebral bodies. Finally, an L3 bone biopsy was performed showing non-specific osteitis 
without granuloma. Acid-fast bacillus (AFB) testing and bacterial cultures including Lowenstein and Coletsos 
were negative. in February 2014, a second MRI demonstrated a typical image of L2-L3 spondylodiscitis with 
pre- and paravertebral abscesses. A new biopsy did not show histological abnormalities, but two samples were 
positive for Staphylococcus epidermidis. Antibiotics were started, without biological improvement. During 
hospitalisation, the patient became confused and developed pyramidal signs, without neurological deficit.  A new 
MRI demonstrated vertebral fracture of L2 with retreat of the posterior wall, mild epidural involvement, partial 
compression of cauda equina, associated with a right psoas abscess (Figure 1). 
 At needle aspiration of the psoas abscess direct examination for acid-fast bacilli (AFB) was positive, A 
4-drug anti-tuberculosis therapy was then initiated. PCR identified M. tuberculosis complex (MBTC), and 
cultures revealed six weeks later M. bovis, finally identified as M. bovis BCG by the French national reference 
center for tuberculosis. Pyrazinamide was discontinued. Surgical treatment was performed due to neurological 
signs and vertebral instability, consisting of L2 vertebrectomy, posterior laminectomy of L3 and T11-L5 
arthrodesis. Ethambutol was stopped after two months. Isoniazid and rifampicin were continued for a total 
duration of three years because of persisting images in the psoas on MRI. Clinical, biological and radiological 
outcome was good. Thirteen months after discontinuing treatments, the patient was considered to be cured. 
 
B. Case 2 
 A 73-year-old man was hospitalised in Rennes University Hospital in July 2017 for low back pain for 11 
weeks. His medical history only reported a urothelial carcinoma, treated with transurethral resection of bladder 
tumor (TURBT) and 9 instillations of BCG, ended in December 2016. He was a retired veterinarian. Low back 
pain onset was reported as brutal, triggered by a bending effort. Secondarily, he developed anorexia, weight loss 
and asthenia. 
 Before his hospitalisation, he was examined with a CT-scan showing an osteolysis of L1 vertebral body. 
He was referred to his oncologist and had a PET-scan as part of a metastatic hypothesis. It showed an uptake of 
L1 and L2 vertebral bodies (Figure 2), with possible epiduritis. For further explorations, he had lumbar spine 
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MRI two months after the first symptoms (Figure 2). A typical vertebral osteomyelitis of L1 and L2 vertebral 
bodies was found, with centro-somatic erosion suggesting a Mycobacterium infection. 
 The physical examination at his admission only showed limited multidirectional lumbar mobility, and 
no neurological impairment. Laboratory analysis showed a normal white blood cell (WBC) count, and a high 
CRP level of 70 mg/L. A first discovertebral puncture was negative on direct examination, MBTC PCR was 
negative, and cultures were sterile after seven days. A puncture of the right psoas abscess showed AFB on direct 
examination. MBTC was identified in a culture six days later. The search for mutation of rpoB that confers 
resistance to rifampicin was negative, and an anti-tuberculosis quadritherapy was started. M. bovis BCG was 
finally identified by PCR and pyrazinamide was stopped. In June 2018, the patient had an excellent evolution, 
with a good tolerance of his nine months of triple therapy. 
 
C. Case 3 
 A 77-year-old man, with a history of gastric adenocarcinoma (1996), urothelial carcinoma (2011) and 
chronic alcoholism, was hospitalised in August 2017 in the rheumatology department of the Saint Philibert 
hospital (Lomme) for insidious onset of low back pain a few weeks earlier. He had been diagnosed with a 
bladder papillary urothelial carcinoma (pTa high-grade) in 2011, treated by transurethral resection in July 2011, 
followed by intravesical BCG therapy from September 2011 to August 2014. He reported inflammatory back 
pain evolving since 2016, without radiculalgia. There was no weight loss. He experienced fever at 38.2°C, 
associated with an increase of CRP levels of 126 mg/L. 
Spine MRI showed an L4-L5 vertebral osteomyelitis with fluid collection developed in the epidural 
space, sheathing the right L5 and S1 roots. A discovertebral biopsy was performed, showing AFB on direct 
examination and the MTBC was detected using real-time PCR. Other tests were unremarkable (negative HIV 
serology, CD4 cell count was normal, no hypogammaglobulinemia, no hypocomplementemia). The thoraco-
abdomino-pelvic CT scan did not find another tuberculous localisation. Blood cultures were sterile and the 
interferon-gamma release assays were negative. The culture was sterile. The patient did not report any contact 
with tuberculosis. Antituberculosis therapy with isoniazid, rifampicin and ethambutol was introduced. Evolution 
was favourable after 12 months of treatment, with a decrease in pain and fever, and a decrease in acute phase 
reactants. At the end of follow-up, he was just diagnosed with lung cancer. 
 
3. Methods 
 
 Based on PubMed research on the 1st January 2019, we used to identify Mycobacterium bovis BCG 
vertebral osteomyelitis the following keywords: “osteomyelitis AND BCG AND bladder”, “spondylodiscitis 
AND BCG AND bladder”, “spondylitis AND BCG AND bladder”. Seventy-five articles had been identified. We 
also used the keywords “aneurysm AND BCG AND bladder”, and looked for vertebral osteomyelitis due to 
overlap with M. bovis BCG infectious aneurysms, identifying 42 articles. 
A total of 117 articles had been identified, and 24 cases had been included. Three other articles had been 
identified through previous reviews (Figure 3). We had three original French cases. 
 
4. Review 
 
Since 1992, 25 cases of M. bovis BCG vertebral osteomyelitis following instillations for bladder cancer have 
been reported in English literature [7–31] and two cases in non-English literature [32, 33]. Other articles with M. 
bovis BCG infection and spinal pain have been published [34–36], but they were not consistent with a vertebral 
osteomyelitis diagnosis. The frequency is possibly underestimated knowing the possible difficulties in 
documenting such an infection, as in two other publications [27, 37]. 
 
A. Clinical characteristics 
 We have collected information from 30 cases (27 literature cases and our 3 new cases), and we have 
listed the main features in Table 1. Diagnostic characteristics are resumed in Table 2. Case 3 was included in our 
review, given the recently proven usefulness of interferon-γ release assay in vertebral osteomyelitis infection 
with Mycobacterium tuberculosis [38], and its recommendation by the IDSA (Infectious Diseases Society of 
America) [39]. 
We have estimated from these articles the period of time between the first and the last BCG instillation 
and the diagnosis (i.e. bacteriological diagnosis). When the dates mentioned in the article were not sufficiently 
detailed, we considered the first and the last instillation time-lap as the same. The median time between 
diagnosis and first or last instillation was 22.5 ± 28.5 months and 14 ± 25.5 months, respectively. At mean, 
patients received 9.4 ± 4.6 instillations of BCG. There was not enough information about the BCG strains to 
establish a difference between them. Seven of 30 cases had a cancer in their medical past history. No one had 
received immunosuppressive therapy between instillation and vertebral osteomyelitis diagnosis. Neoplasia was 
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considered as cured, in remission [20], or localized [10, 23]. No patients had received DMARDs for rheumatic 
condition, and one had psoriasis without musculoskeltal disorder. 
 
 All M. bovis BCG vertebral osteomyelitis cases occurred in men of 73.4 ± 8.7-year-old. Twenty-six 
cases involved two contiguous vertebrae, and two cases one vertebra. Half of infections affected the thoracic 
spine (from T1-T2 to T12-L1), and the other half affected the lumbar spine (from L1-L2 to L5-S1). No cervical 
osteomyelitis was reported. Back pain was almost always present (97%). The median of back pain duration at 
diagnosis was 5 (1-9) months, and the median period of time between the last instillation and back pain was 5 (0-
16.5) months. No peripheral skeletal involvement had been reported. 
Clinically, fever was reported only in 20% of cases, 75% developed anorexia and/or weight loss and/or 
asthenia. Sensitivo-motor deficit was present at diagnosis in 42% of cases.  
On imaging (CT scan and/or MRI) 70% had epiduritis or epidural abscesses (Figure 1), and 47% had 
paravertebral/psoas abscesses (Figure 1 and 2). Other infectious locations occurred in nine cases, mostly 
abdominal aortic aneurysms.  
Biologically, 77% of patients had CRP > 5 mg/l, and 21% an elevated WBC count. The tuberculin test 
was negative for 5 out of 6 patients, and the seven IFN-gamma tests were all negative (only one patient receive 
both tests, both negative). Biopsy showed a granuloma in 60% of cases, of which 56% was necrotic. 
Mycobacterium bovis BCG was almost always identified through cultures. 
The direct exam was positive in 55% of bacteriological samples. All molecular tests and PCR were 
positive. Bacteriological identification was done through CT-guided biopsy with 79% positivity, and through 
surgical biopsy or abscess puncture which were always positive. When CT-guided biopsies were negative, 
diagnosis was made with surgical biopsy in two cases, and with abscess puncture in two cases. Abscess puncture 
was the only procedure used in four cases. 
 
B. Treatment and outcomes 
Frequently, the classical anti-tuberculosis therapy was started, and then Pyrazinamide was stopped when 
BCG was identified due to BCG natural resistance[40]. Isoniazid, rifampicin and ethambutol were normally used 
throughout the treatment period. Nevertheless, antibiotic modalities were heterogeneous (Table 1). Treatment 
duration, known for 20 cases, was 12.1 ± 7.0 months.  
The outcome was known for 14 patients with 18.5 months of mean follow up: 12 cases were considered 
cured, and 2 died from cardiovascular causes without vertebral osteomyelitis symptoms. Fifty percent had one or 
more cases of spine surgery, (ranging from one to three surgeries). Among them, five patients had spinal 
arthrodesis during the follow-up: three for neurological worsening, one for persistent root pain, and one for 
vertebral instability.  
 
C. Comparison of M. bovis BCG with M. tuberculosis 
Compared to vertebral osteomyelitis due to M. tuberculosis [41], M. bovis BCG vertebral osteomyelitis 
seems to involved an older population with a male predominance, probably due to the bladder cancer population. 
However, we noticed that all cases in this review were men, while 74.1% of non-muscle-invasive bladder 
carcinoma in the United States are male [42]. About clinical presentation, lumbar and thoracic involvement of 
BCG vertebral osteomyelitis were consistent with literature, but no cases of nonadjacent multiple-level 
involvement were reported with BCG after bladder instillation. Neurological complications at diagnosis and 
psoas abscesses prevalence seems to be higher in BCG than tuberculosis. 
In contrast of tuberculosis, there was no other sites of M. bovis BCG vertebral osteomyelitis infection, 
whereas vertebral Pott’s disease is frequently associated to pulmonary tuberculosis at diagnosis. We assumed 
that’s it’s probably due to the gateway of Mycobacteria: through airway contamination leading to pulmonary 
tuberculosis, and through catheterization leading to local urinary reaction or systemic reaction which are 
sometimes treated with antituberculosis treatment, decreasing risk of other infection. 
 
D. Pathogenesis discussion 
 BCG instillations are a cornerstone for superficial bladder carcinoma treatment, and they have changed 
the prognosis of this disease [4, 5]. Septic side effects are rare, between 0.4% and 1/15,000 according to Lamm 
[5], and the benefit of the treatment remains higher than the risk of such events. However, other distant 
infections are described in the literature, mostly vascular aneurysms in a recent literature review [43], but also 
disseminated infections also called BCGitis [44], small-vessel central nervous system vasculitis [45] and even 
nosocomial infections, including vertebral osteomyelitis [46]. Some risk factors of distant infections could be 
suggested: a traumatic catheterisation during instillation [5], haematuria, instillations in the few days around an 
urological trauma [28] (pelvic radiation, surgery, bladder resection), arterial catheterisation [13], and general 
immunosuppressive factor such as HIV infection.  
Pathogenesis of M. bovis BCG-associated infections following instillations can be supported in three 
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ways. First, through the pelvic lymphatic drainage system, particularly for psoas abscesses. Even if iliopsoas 
abscess pathogenesis is not clear, haematogenous or lymphatic spread is commonly admitted [47]. Such 
abscesses can be linked to BCG spread from bladder to the lymph nodes, particularly those closely related to the 
iliopsoas muscle, such as the common iliac and paravertebral lymph nodes. However, an exclusive lymphatic 
pathogenesis underlies an infection by contiguity only with vertebrae which have an anatomical relationship with 
iliopsoas, i.e. T12 to L4. Secondarily, as recently suggested [28], through the vertebral venous plexus (known as 
Batson's venous plexus). Once again, a venous spread of BCG does not explain thoracic osteomyelitis. Finally, 
through an arterial route: Higashi et al. [43] suggested a septic aneurysm pathogenesis from vasa vasorum, or 
directly by adhesion on atherosclerotic degeneration in a review of 29 cases (including three common cases of 
patients with vertebral osteomyelitis and infectious aneurysm). 
Considering these vascular infections and the pathogenesis of haematogenous spread in vertebral 
osteomyelitis, arterial dissemination seems to be the principal way, as suggested by Civen et al. [10] who 
described a positive blood culture of BCG. However, there seems to be an association between infectious 
aneurysm and vertebral osteomyelitis: among the 17 cases including L1 to L4 vertebral involvement (i.e., 
vertebrae having a direct anatomical relationship with the abdominal aorta), there were five out of six cases of 
infectious aneurysm, and only one thoracic osteomyelitis was associated with infectious aneurysm. This higher 
frequency of aneurysms in lumbar osteomyelitis suggests pathogenesis other than the arterial route for 
aneurysms. Finally, a simultaneous infectious aneurysm may also seem to be associated with cardiovascular risk, 
because of a more frequent cardiovascular medical history (Table 1). 
Mycobacterium bovis BCG identification is crucial in M. bovis BCG associated osteomyelitis. Culture is 
the first step, but a specific identification has to be done. Oldest cases used high-pressure liquid chromatography 
(HPLC), which has been nowadays replaced by molecular technics. Multiplex PCR targeting specific regions of 
Mycobacterium spp. genomes can now differentiate with a total specificity [48] M. bovis BCG from the others 
mycobacteria. It means that, when vertebral osteomyelitis is suspected in a patient with medical history of BCG 
instillations for bladder carcinoma, AFB on direct examination or positive culture for MTBC must have the 
biologist carry out the precise identification of the strain by mutliplex PCR, including BCG detection, the 
therapeutic impact being significant. 
 Other related events following BCG instillations were described, such as ReA [6] with a HLA-B27 (or 
B51 in the Japanese population) association, suggesting a Th17 response. On the other hand, the anti-tumour 
effect of BCG therapy is based on a Th1 response [49] as well as the anti-infectious response. Tumour recurrence 
could not be evaluated in this review but occurred in eight patients. Based on purely immunological 
considerations, we assume that there could be a link between tumour recurrence and these signalling pathways. 
M. bovis BCG associated infections could be correlated to a lack of Th1 lymphocyte polarisation, and thus an 
increased risk of recurrence, making M. bovis BCG-associated infections a risk factor for the inefficacy of BCG 
instillations. In the same way, Th17 polarisation observed in ReA could reduce a Th1 response (because of the 
exclusive nature of the polarisation [50]). Such assumptions need more specific studies to evaluate correlations 
between tumour recurrence, infections and immunological reactions. 
 
 In conclusion, when vertebral osteomyelitis is suspected in a man with a medical history of bladder 
carcinoma treated with BCG instillations, M. bovis BCG osteomyelitis must be sought even if the last instillation 
was months before. A direct exam showing AFB and positive cultures followed by multiplex PCR are used for 
bacteriological diagnosis. The presence of aneurysms at osteomyelitis diagnosis should be investigated because 
of its potential life-threatening complications. The treatment is not codified, but the pyrazinamide resistance 
must be known. The duration of anti-tuberculosis therapy is heterogeneous, and individual adaptation has to be 
done, regards to the septic severity, neurological deficit, or treatment adverse effects. 
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Figure 2. (a) MRI Axial T1 with Fat Sat sequence and Gadolinium injection showing epiduritis with partial 
cauda equina compression, and voluminous right psoas abscesses (b) MRI Sagittal T2 with Fat Sat, showing 
hypersignal of L1 and L2 vertebral body with a vertebral fracture of L2 and retreat of posterior wall. 
 
Figure 3. (a) 18F-FDG PET-CT showing FDG uptake on L1-L2 vertebral bodies (b) MRI Axial T1-weighted 
with contrast showed hypersignal of L2 body and a well circumscribed right psoas abscess with Gadolinium 
enhancement, without epiduritis. (c) MRI Sagittal STIR sequence of the lumbar spine showed hypersignal of L1 
and L2 vertebral bodies, with hypersignal in the L1-L2 disc confirming the discitis. White arrow: centro-somatic 
erosion suggesting a Mycobacterium infection. 
 
Table 1. Clinical, biological, bacteriological and imaging features of 30 reported cases of M. 
bovis BCG vertebral osteomyelitis after instillations of BCG for bladder cancer. 
 
 Results 
Clinical Characteristics 
Men, n (%) 
 
30 (100%) 
Age (years) mean ± SD 73,4 ± 8,7 
Back pain, n (%) 29/30 (97%) 
Duration of back pain (months), median ± IQR 5 ± 4 (22/30) 
Median time (in months ± IQR) between diagnosis and: 
    - first instillation of BCG 
    - last instillation of BCG 
 
22.5 ± 28.5 (30/30) 
14 ± 25.5 (30/30) 
Period of time between last instillation and back pain (in months),  
median ± IQR 
 
5 ± 11.5 (22/30) 
Number of instillations, mean ± SD 9.4 ± 4.6 (19/30) 
Fever, n (%) 4/20 (20%) 
Weight loss, n (%) 12/20 (60%) 
Night sweats, n (%)  3/20 (15%) 
Sensitivo-motor deficit, n (%) 11/26 (42%) 
Other infectious locations: 
    - infectious aneurysm, n (%) 
    - others 
 
9/30 (30%) 
6/30 (20%) 
3/30 (10%) 
 
 
Biological Characteristics 
ESR > 20 mm/1st h, n (%) 
 
8/14 (57%) 
High WBC, n (%) 4/19 (21%) 
CRP > 5 mg/l, n (%) 10/13 (77%) 
 
 
Morphological Characteristics 
CT scan and/or MRI: 
    - epidural involvement 
    - paravertebral 
    - psoas abscess 
 
 
21/30 (70%) 
5/30 (17%) 
10/30 (33%) 
 
Bacteriological Characteristics 
Positive bacterial identification/number of procedures: 
    - abscess puncture 
    - CT guided biopsy 
    - surgical biopsy 
 
 
9/9 (100%) 
15/19 (79%) 
13/13 (100%) 
Positive bacterial identification/number of tests: 
    - acid-fast bacilli 
    - cultures 
    - molecular tests 
 
11/20 (55%) 
28/30 (93%) 
14/14 (100%) 
Histological biopsy: 
    - presence of granuloma, n (%) 
    - necrotizing granuloma, n (%) 
 
9/15 (60%) 
5/9 (56%) 
 
Antibiotics therapy duration (months), mean ± SD 12.1 ± 7.0 
SD: standard deviation; IQR: interquartile range; ESR: erythrocyte sedimentation rate; WBC: white blood cell count; CRP: 
C-reactive protein. 
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Table 2. Description of 30 cases of M. bovis BCG vertebral osteomyelitis after instillations of BCG for bladder cancer. 
 # Periods of time are the same when the dates mentioned in the article were not enough detailed; HBP Hyper Blood Pressure; NR: not reported; AAA: abdominal aortic aneurysm; INH: isoniazid; RIF: rifampicin; ETH: ethambutol;  
Authors Year of 
article 
Age / 
Sex 
Comorbidities Period of time 
(months) between 
instillation and 
diagnosis # 
First            Last 
Back pain 
duration 
(months) 
Number of 
instillations 
Involved 
Levels 
Other BCG 
infection 
CRP 
(mg/L) 
Anti-tuberculosis therapy Treatment 
duration 
Neurological 
symptoms on 
admission  
Spine 
surgery 
Katz and al. 1992 66 / M Smoking 15 3 NR 12 L4-L5 - NR INH + RIF NR Yes Yes 
Stone and al. 1993 80 / M 
Coronary artery bypass, Ventricular 
fibrillation 
5 3,5 3 6 L5-S1 Pacemaker NR INH + RIF then INH + ETH 4 NR No 
Fishman and al. 1993 90 / M - 16 15 1 6 T11-T12 - NR INH + RIF + ETH NR No No 
Civen and al. 1994 81 / M 
HBP, Atrial fibrillation, Prostate 
cancer 
7 3,5 1 8 T12-L1 Blood Culture NR INH + RIF 12 No Yes 
Morgan and 
Iseman 
1996 77 / M Traumatic fracture of T12 80 8,5 6 12 T12-L1 - NR 
INH + RIF, then quadritherapy and then 
INH + RIF 
25 
(10+9+6) 
NR Yes 
Rozenblit and al. 1996 76 / M Myocardial infarction, Hearth failure 69 69 1 NR L4 AAA NR INH + RIF NR No No 
LaBerge and al. 1999 75 / M Coronary artery disease 22 22 2 NR L3-L4 AAA NR NR NR NR No 
Aljada and al. 1999 79 / M 
HBP, Smoking, Parkinson's disease, 
Myocardial infarction, Peripheral 
arterial disease  
30 14 18 20 L3 - NR Quadritherapy then INH + RIF 12 Yes Yes 
Abu-Nader and 
Terrell 
2002 76 / M 
Benign prostatic hypertrophy, 
Psoriasis 
84 84 6 6 T6-T7 - NR Quadritherapy then INH + RIF + ETH 12 Yes No 
Dahl and al. 2005 69 / M Appendicitis, colorectal cancer, AAA 12 12 NR NR L3-L4 AAA NR Quadritherapy then INH + RIF 9 Yes Yes 
Nikaido and al. 2007 86 / M HBP 23 21 NR 8 T12-L1 - 16 INH + RIF + ETH NR No No 
Mavrogenis and al 2009 72 / M 
Benign prostatic hypertrophy, 
lumbarthrosis 
120 105 6 12 L3-L4 - NR Quadritherapy then INH + RIF + ETH 12 Yes Yes 
Colebatch and 
Mounce 
2010 67 / M Testicular cancer 60 60 36   L4-L5 - Normal Quadritherapy then INH + RIF 7 NR No 
Josephson and al. 2010 75 / M Mycosis fungoides 35 6 6 21 L1-L2 
Cerebral 
tuberculoma 
NR 
Quadritherapy, INH + RIF + ETH and then 
INH + RIF 
12 (2+10) Yes No 
Patel and al. 2010 66 / M - 9 8 5 6 T10-T11 - NR INH + RIF + ETH 12 No No 
Obaid and al. 2011 67 / M - 11 9,5 5 6 L1-L2 - NR INH + RIF + ETH 9 No Yes 
Samadian and al. 2013 94 / M 
Chronic kidney disease, Prostate 
cancer 
23 23 18 NR L1-L2 AAA Normal NR NR No No 
Stahl and al. 2013 60 / M Clear cell carcinoma 23 23 NR NR T11-T12 - NR NR NR No No 
Santbergen and al. 2013 58 / M 
Myocardial infarction, ischemic stroke 
et prostatectomy 
39 39 NR NR T8-T9 AAA 10 
Quadritherapy + moxifloxacin, then  RIF + 
INH + moxifloxacin 
12 No No 
Newman and al. 2014 80 / M - 41 17 5 NR T9-T10 - NR INH + RIF + ETH and then INH + RIF 8 (2+6) Yes Yes 
Lara-Oya and al. 2015 78 / M 
Parkinson disease, vertebral 
osteomyelitis of T11-T12 (S. aureus) 
36 36 NR NR T11-T12 - 61 INH + RIF + ETH 12 Yes Yes 
Dabrowska and al. 2015 67 / M HBP 10,5 6 5 9 T10-T11 - Normal INH + RIF + ETH, then INH + RIF NR Yes Yes 
Białecki and al. 2016 66 / M - 60 60 NR NR T10-T11 - 30 Quadritherapy, then INH + RIF + PZA NR Yes Yes 
Mackel and al. 2016 64 / M - 11 6 6 5 T11-T12 - 40 
INH + ETH + rifabutine + cycloserine + 
moxifloxacin + capreomycin 
12 No Yes 
Miyazaki and al. 2016 82 / M - 16 14 2 8 T5-T6 - 7,5 INH + RIF + ETH 6 No Yes 
Seegobin and al. 2017 62 / M - 14 3 1 12 T4-T5 - NR INH + RIF + ETH 9 Yes Yes 
Kusakabe and al. 2018 76 / M 
Cervical laminoplasty, Idiopathic 
skeletal hyperostosis, HBP, Diabetes 
 
14 12.5 5 6 L2-L3 AAA  INH + RIF + ETH NR No Yes 
Case n°1 - 65 / M Weaned smoking, HBP 12 9 3 6 L2-L3 - 123 Quadritherapy, then INH + RIF + ETH 9 No Yes 
Case n°2 - 71 / M Atrial fibrillation 11 7 2 9 L1-L2 - 70 
Quadritherapy, then INH + RIF + ETH and 
then INH + RIF 
36 
(2+1+33) 
No No 
Case n°3 - 77 / M Gastric adenocarcinoma, Alcoholism 82 48 NR NR L4-L5 - 126 INH + RIF + ETH 12 No No 
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Figure 1. (a) MRI Axial T1 with Fat Sat sequence and Gadolinium injection showing 
epiduritis with partial cauda equina compression, and voluminous right psoas abscesses (b) 
MRI Sagittal T2 with Fat Sat, showing hypersignal of L1 and L2 vertebral body with a 
vertebral fracture of L2 and retreat of posterior wall. 
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Figure 2. (a)18F-FDG PET-CT showing FDG uptake on L1-L2 vertebral bodies (b) MRI 
Axial T1-weighted with contrast showed hypersignal of L2 body and a well circumscribed 
right psoas abscess with Gadolinium enhancement, without epiduritis. (c) MRI Sagittal STIR 
sequence of the lumbar spine showed hypersignal of L1 and L2 vertebral bodies, with 
hypersignal in the L1-L2 disc confirming the discitis. White arrow: centro-somatic erosion 
suggesting a Mycobacterium infection60. 
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Figure 3. Flow chart of literature review 
PubMed search with “osteomyelitis AND 
BCG AND bladder”, “spondylodiscitis 
AND BCG AND bladder”, 
“spondylodiscitis AND BCG AND 
bladder”, “aneurysm AND BCG AND 
bladder” = 141 
117 after duplicates 
removing 
24 cases of M. bovis BCG 
vertebral osteomyelitis in 
literature 
93 results excluded: 
- 44 other infections 
- 37 of reactive arthritis 
- 3 recommendations 
- 5 letters to editor 
- 2 other reasons 
- 1 vertebral osteomyelitis 
without BCG instillation46 
- 1 vertebral abscess36 
30 cases reviewed 
Other sources: 
- 2 results from a 
previous review31 
- 1 from article 
references15 
- 3 new cases 
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